Journal Article

Evaluation of the CEDIA<sup>™</sup> DAU Assays and the AxSym<sup>™</sup> System for the Analysis of Cannabinoids in Whole Blood

Joan C. Cagle, H. Horton McCurdy, Y. Mary Pan, Kim J. Ayton, William H. Wall and Everett T. Solomons

in Journal of Analytical Toxicology

Volume 21, issue 3, pages 213-217
Published in print May 1997 | ISSN: 0146-4760
Published online May 1997 | e-ISSN: 1945-2403 | DOI: http://dx.doi.org/10.1093/jat/21.3.213
Evaluation of the CEDIA™ DAU Assays and the AxSym™ System for the Analysis of Cannabinoids in Whole Blood

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)

GO

Show Summary Details

Preview

The Microgenics CEDIA DAU (EIA) and the Abbott AxSym system (FPIA) cannabinoids assays were evaluated for their combined effectiveness in the analysis of cannabinoids in whole blood. Blood samples were treated with acetone, evaporated, and reconstituted, and the supernatant was analyzed by the EIA cannabinoids assay. Blood samples determined positive by EIA were then treated with acetonitrile and sodium sulfate, and the resultant protein-free supernatant was analyzed using the FPIA cannabinoids assay. A total of 98 blood samples determined to be presumptively positive by both EIA and FPIA were further analyzed for the presence of 11-nor-carboxy-Δ9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH). All 98 blood samples could be confirmed for the presence of THCCOOH by gas chromatography-mass spectrometry (GC-MS) at concentrations greater than the 10 ng/mL cutoff. The GC-MS results were found to correlate significantly better with those of the FPIA cannabinoids assay (r = 0.75) than with EIA (r = 0.22). Procedures for the rapid analysis of whole blood for cannabinoids using CEDIA DAU reagents and the AxSym system are presented.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.